


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for inducing promotion of neural cell differentiation of target cells comprising contacting said target cells for a suitable period of time with an effective amount of a compound of the general Formula I



wherein

Y is $-(CH_2)_m-$, $-CH(OH)-$ or $-C(=O)-$ and m is $[[0-3]]$ 1-3;

X is H, alkyl, $-CH_2OH-$, CH_2Oacyl or $-CH_2acyl$; and

R is H, a cation, alkyl or optionally substituted aryl;

~~provided that when Y is $-(CH_2)_m-$, $m=0$, and R is H or cation, X is not CH_2Oacyl .~~

2. (original) A method for promoting neural activity in an individual comprising administering to the

individual in need an effective amount of a compound of the general Formula I of Claim 1.

3. (previously presented) A method according to Claim 2, wherein said neural activity is selected from the group consisting of promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased portion of the brain and nerve rescue.

4. (previously presented) A method for the treatment of disorders and diseases which can be treated by promoting neural cell differentiation and/or neural activity comprising administering to a person in need a therapeutically effective amount of a compound of Formula I of Claim 1.

5. (previously presented) A method according to Claim 4, wherein said disorders and diseases are mental disorders or diseases which are at least one of dementia mental disorders and neuro-degenerative disorders or diseases.

6. (currently amended) A method according to Claim 4, wherein said mental disorder or disease is schizophrenia ~~or~~ dementia.


7. (original) A method according to Claim 4,
wherein said disorders and diseases are neurodegenerative
disorders or diseases.

D1
only
8. (currently amended) A method according to claim
1 wherein the compound of formula I is selected from the group
consisting of

- i. 1,3 cyclic glycerophosphate;
- ~~ii. 1,2 cyclic glycerophosphate;~~
- ~~iii. phenyl 1,3 cyclic glycerophosphate;~~
- ~~iv. phenyl 1,2 cyclic glycerophosphate;~~
- ~~v. 1,3 cyclic propanediol phosphate;~~
- ~~vi. 1,2 cyclic propanediol phosphate;~~
- ~~vii. phenyl 1,3 cyclic propanediol phosphate;~~
- ~~viii. phenyl 1,2 cyclic propanediol phosphate;~~
- ~~ix. cyclic dihydroxyacetone phosphate; and~~
- ~~x. phenyl cyclic dihydroxyacetone phosphate.~~

9-16. (canceled)

17. (currently amended) A method for promoting
neural activity in an individual comprising administering to
the individual in need an effective amount of a compound of
the general formula I



wherein

Y is $-(CH_2)_m-$, $-CH(OH)-$ or $-C(=O)-$ and m is [[0-3;]]1-3;


X is H, alkyl, $-CH_2OH-$, CH_2Oacyl or $-CH_2acyl$; and

R is H, a cation, alkyl or optionally substituted aryl;

~~provided that when Y is $-(CH_2)_m-$, $m=0$, and R is H or cation, X is not CH_2Oacyl ;~~

wherein said neuronal activity is selected from the group consisting of promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased portion of the brain and nerve rescue.

18. (currently amended) A method for the treatment of disorders and diseases, other than dementia, which can be treated by promoting neural cell differentiation and/or neural activity, the method comprising administering to a person in need a therapeutically effective amount of a compound of Formula I



wherein

Y is $-(CH_2)_m-$, $-CH(OH)-$ or $-C(=O)-$, and m is [[0-3]] 1-3;

X is H, alkyl, $-CH_2OH-$, CH_2Oacyl or $-CH_2acyl$; and

R is H, a cation, alkyl or optionally substituted aryl;


~~provided that when Y is $-(CH_2)_m-$, $m=0$, and R is H or cation, X~~
~~is not CH_2Oacyl .~~

19. (original) A method according to claim 18,
 wherein said disorders and diseases are mental disorders or
 diseases.

20. (previously presented) A method according to
 claim 18 , wherein said mental disorder or disease is
 schizophrenia.

21. (previously presented) A method according to
 Claim 18 , wherein said mental disorder is a learning
 disability.

22. (original) A method according to claim 18, wherein said disorders and diseases are neurodegenerative disorders or diseases.

 23. (previously presented) A method according to Claim 18, wherein said neurodegenerative disorder or disease is Alzheimer's disease or Parkinson's disease.

24. (previously presented) A method according to Claim 18, wherein said disorders or diseases result from exposure of an individual to harmful environmental factors or from a mechanical injury.

25. (previously presented) A method according to Claim 18, for the treatment of nerve rescue after nerve injury.

26. (currently amended) A method according to claim 18 where the general formula I is selected from the group consisting of

- i. 1,3 cyclic glycerophosphate;
- ~~ii. 1,2 cyclic glycerophosphate;~~
- iii. phenyl 1,3 cyclic glycerophosphate-P;
- ~~iv. phenyl 1,2 cyclic glycerophosphate;~~
- viii. 1,3 cyclic propanediol phosphate;
- ~~vi. 1,2 cyclic propanediol phosphate;~~

- Q/*
only
- ~~viii~~iv. phenyl 1,3 cyclic propanediol phosphate;
 - ~~viii~~. ~~phenyl 1,2 cyclic propanediol phosphate;~~
 - ~~ix~~v. cyclic dihydroxyacetone phosphate; and
 - ~~xvi~~. phenyl cyclic dihydroxyacetone phosphate.

27-36. (canceled)

37 (new): A method according to claim 4, wherein
said mental disorder or disease is dementia.
